Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. (ARMP): 3 pipeline candidates · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.6 months
D/E -1.22
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Armata Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$253.7M
Cash
$8.9M
Quarterly Burn
$5.8M
Runway
4.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
42
Total value held
$20.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 732,056 | $7.5M |
| millennium management llc | 257,992 | $2.6M |
| 683 capital management, llc | 137,000 | $1.4M |
| geode capital management, llc | 114,555 | $1.2M |
| edgewood management llc | 100,000 | $1.0M |
| sei investments co | 74,192 | $760K |
| vanguard fiduciary trust co | 67,864 | $695K |
| blackrock, inc. | 65,050 | $666K |
| susquehanna international group, llp | 64,759 | $663K |
| informed momentum co llc | 60,955 | $624K |
Showing top 10 of 42 institutional holders of Armata Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Armata Pharmaceuticals, Inc.'s pipeline?
Armata Pharmaceuticals, Inc. (ARMP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Armata Pharmaceuticals, Inc.'s lead drug candidate?
Armata Pharmaceuticals, Inc.'s most advanced tracked candidate is AP-PA02 (Phase 2) for Chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis and non-cystic fibrosis bronchiectasis.
What is Armata Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Armata Pharmaceuticals, Inc. has approximately 4.6 months of cash runway.
What is Armata Pharmaceuticals, Inc.'s market capitalization?
Armata Pharmaceuticals, Inc.'s market capitalization is approximately $253.7M.
Who is the CEO of Armata Pharmaceuticals, Inc.?
Dr. Deborah L. Birx M.D. is the chief executive officer of Armata Pharmaceuticals, Inc. (ARMP).
Get the full picture on Armata Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.